SEARCH

SEARCH BY CITATION

References

  • 1
    Must, A, Spadano, J, Coakley, EH, Field, AE, Colditz, G, Dietz, WH. The disease burden associated with overweight and obesity. JAMA 1999; 0: 15239.
  • 2
    Davì, G, Guagnano, MT, Ciabattoni, G, Basili, S, Falco, A, Marinopiccoli, M, Nutini, M, Sensi, S, Patrono, C. Platelet activation in obese women. Role of inflammation and oxidant stress. JAMA 2002; 288: 200814.
  • 3
    Alessi, MC, Peiretti, F, Morange, P, Henry, M, Nalbone, G, Juhan-Vague, I. Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 8607.
  • 4
    Samad, F, Loskutoff, DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med 1996; 2: 56882.
  • 5
    Friedman, JM, Halaas, JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 76370.
  • 6
    Considine, RV, Sinha, MK, Heiman, ML, Kriauciunas, A, Stephens, TW, Nyce, MR, Ohannesian, JP, Marco, CC, McKee, LJ, Bauer, TL, Caro, JF. Serum immunoreactive leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 2925.
  • 7
    Nakata, M, Yada, T, Soejima, N, Maruyama, I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999; 48: 4269.
  • 8
    Loffreda, S, Yang, SQ, Lin, HZ, Karp, CL, Brengman, ML, Wang, DJ, Klein, AS, Bulkley, GB, Bao, C, Noble, PW, Lane, MD, Diehl, AM. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 5765.
  • 9
    Sierra-Honigmann, MR, Nath, AK, Murakami, C, Garcia-Cardena, G, Papapetropoulos, A, Sessa, WC, Madge, LA, Schechner, JS, Schwabb, MB, Polverini, PJ, Flores-Riveros, JR. Biological action of leptin as an angiogenic factor. Science 1998; 281: 16836.
  • 10
    Bouloumié, A, Marumo, T, Lafontan, M, Busse, R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999; 13: 12318.
  • 11
    Mark, AL, Correia, ML, Rahmouni, K, Haynes, WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20: 124550.
  • 12
    National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 103957.
  • 13
    World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity. WHO/NUT/NCD/98.1. Geneva: World Health Organization, 1997.
  • 14
    Miller, GJ, Bauer, KA, Barzegar, S, Foley, AJ, Mitchell, JP, Cooper, JA, Rosenberg, RD. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost 1995; 73: 826.
  • 15
    Blann, AD, McCollum, CN, Lip, GY. Relationship between plasma markers of endothelial cell integrity and the Framingham cardiovascular disease risk-factor scores in apparently healthy individuals. Blood Coagul Fibrinolysis 2002; 13: 5138.
  • 16
    Conlan, MG, Folsom, AR, Finch, A, Davis, CE, Sorlie, P, Marcucci, G, Wu, KK. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 3805.
  • 17
    Kienast, J, Thompson, SG, Raskino, C, Pelzer, H, Fechtrup, C, Ostermann, H, Van De Loo, J. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relation to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993; 70: 5503.
  • 18
    Giannitsis, E, Siemens, HJ, Mitusch, R, Tettenborn, I, Wiegand, U, Schmucker, G, Sheikhzadeh, A, Stierle, U. Prothrombin fragments F1+2, thrombin antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. Int J Cardiol 1999; 68: 26974.
  • 19
    Cooper, JA, Miller, GJ, Bauer, KA, Morrissey, JH, Meade, TW, Howarth, DJ, Barzegar, S, Mitchell, JP, Rosenberg, RD. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 281622.
  • 20
    Yudkin, JS, Stehouwer, CD, Emeis, JJ, Coppack, SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 9728.
  • 21
    Leyva, F, Godsland, IF, Ghatei, M, Proudler, AJ, Aldis, S, Walton, C, Bloom, S, Stevenson, JC. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol 1998; 18: 92833.
  • 22
    Bullo, M, Garcia-Lorda, P, Megias, I, Salas-Salvado, J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003; 11: 52531.
  • 23
    Blackburn, G. Effect of degree of weight loss on health benefits. Obes Res 1995; 3: 211s6s.
  • 24
    Van Dielen, FM, Van't Veer, C, Buurman, WA, Greve, JW. Leptin and soluble leptin receptor levels in obese and weight-losing individuals. J Clin Endocrinol Metab 2002; 87: 170816.
  • 25
    Farooqi, IS, Keogh, JM, Kamath, S, Jones, S, Gibson, WT, Trussel, R, Jebb, SA, Lip, GY, O'Rahilly, S. Partial leptin deficiency and human adiposity. Nature 2001; 414: 345.